Tag: Motley Fool

  • Why investors don’t need to worry about rising inflation

    Rising inflation is nothing to worry about for stock investors, according to multiple experts.

    The current economic recovery after the COVID-19 downturn has ironically been a bogey for growth shares

    A fear of subsequent rising inflation and interest rates has seen the valuations of growth businesses hammered over the last 6 months.

    The S&P ASX All Technology Index (ASX: XTX), for example, has sunk 8% since the start of the year. It’s dropped almost 15% off its 52-week high.

    “It’s been a violent selloff out there,” Forager Funds chief executive Steve Johnson said in a video to investors this week.

    “Good quality tech companies are down with Xero Limited (ASX: XRO) 23% off its peak and even the poster child for the growth sector, Afterpay Ltd (ASX: APT), is now down 45% from its peak just a couple of months ago.”

    So should we be worried? How long will growth stocks be out of favour?

    Remember how we worried machines would take our jobs?

    Montgomery Investments chief investment officer Roger Montgomery is shocked at how short people’s memories are.

    “Prior to COVID, one narrative occupying our imaginations was the rise of automation,” he said in a blog post recently.

    “The ‘jobs for machines, life for people’ narrative had become so concerning to some it inspired talk of a universal basic wage.”

    And since that talk interest rates had sunk even lower, triggering “a near-vertical acceleration in IT spending” everywhere.

    So for Montgomery the current inflation worries are temporary. The pre-COVID disinflationary forces still persist and will return after the virus has been dealt with.

    “It is important for investors to remember the long-term narrative,” he said.

    “Inflation will bounce around in the short and even medium term but structurally it appears to be heading interminably down. Lower inflation appears to be a structural reality.”

    A ripe buying opportunity

    The longer-term low inflation outlook means investors need to put their fears aside and grab the current buying opportunities.

    “We’ve got a good list of probably 8 to 10 businesses that we’d love to own at the right price that are a lot closer to it today,” said Johnson.

    “So if this goes on for a few more months, you can expect to see a few more new names in the Australian Fund portfolio.”

    Montgomery agreed, saying there are now many decent stocks going for a tempting discount. 

    “Historically, economic growth combined with disinflation is an ideal time to be in equities,” he said.

    “Current and intermittent weakness in the share prices of high quality companies with bright long-term growth prospects should be seen as a classic contrarian opportunity.”

    After vaccinations are rolled out and the pandemic is long forgotten, automation and digitisation of work will once again re-enter public discourse.

    “We will return to debating a response to job losses from the rise of machines, AI and robots,” said Montgomery.

    “And while the impact on wages and jobs will be negative, in the absence of any legislative or regulatory response, the marginal cost for business will decline and profits will rise.”

    The post Why investors don’t need to worry about rising inflation appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/3ifOSPt

  • Top broker still sees value in the Pro Medicus (ASX:PME) share price

    The Pro Medicus Limited (ASX: PME) share price was on form on Thursday.

    The health imaging company’s shares rose over 3% to $47.61.

    This means the Pro Medicus share price is now up almost 36% since the start of the year.

    Why did the Pro Medicus share price storm higher?

    Investors were bidding the Pro Medicus share price higher on Thursday after the company announced a deal with healthcare giant Mayo Clinic.

    According to the release, the company’s Visage Imaging business has signed a multi-year research collaboration agreement with Mayo Clinic that will facilitate development and commercialisation activities in the field of artificial intelligence (AI), leveraging the Visage AI Accelerator platform.

    Can its shares go higher?

    According to a note out of Goldman Sachs, its analysts still see value in Pro Medicus’ shares.

    This morning the broker has retained its buy rating and $53.80 price target on the company’s shares. Based on the latest Pro Medicus share price, this implies potential upside of 13% over the next 12 months.

    Goldman commented: “PME today announced that it has signed a multi-year research collaboration with Mayo Clinic, one of the leading academic healthcare networks in the US. This agreement will facilitate the two parties’ research efforts around Artificial Intelligence in the field of radiology, with the primary aim of developing/commercialising new products.”

    “Following today’s announcement, we highlight that PME has now established R&D collaborations with three different, world-renowned healthcare networks. These efforts have already yielded an interesting commercial opportunity, which could provide a material revenue contribution from FY22. We believe the strategy of partnering with the leading academics helps to maximise the value and competitive advantage of PME’s technology proposition,” the broker commented.

    In light of the above, this could make it worth considering Pro Medicus at the current level.

    The post Top broker still sees value in the Pro Medicus (ASX:PME) share price appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/3cbBOGX

  • 3 reasons why the Volpara (ASX:VHT) share price could be a buy

    The Volpara Health Technologies Ltd (ASX: VHT) share price could be an interesting one to look at with the current price being $1.26.

    What is Volpara?

    Volpara is a New Zealand technology business that is listed on the ASX.

    It operates a software-as-a-service (SaaS) model that utilises AI to improve the early detection of breast cancer by analysing breast images, called mammograms, and associated patient data.

    Volpara provides personalised breast care through clinical decision support and proactive management tools. It wants to provide a cost effective reduction of breast cancer deaths, there are around 600,000 deaths globally each year.

    Here’s why Volpara could be a good option:

    Growing average revenue per user (ARPU)

    Volpara has an increasing average revenue per user. ARPU is the average revenue achieved per women screened per year at a site

    ARPU has risen to US$1.40. The CRA Health business that Volpara recently acquired is growing strongly and has ARPU of US$1.70. The company said that its ARPU rose by over 30% between the second quarter of FY20 and the second quarter of FY21 despite COVID-19 impacts. 

    The business continues to track acquisition opportunities that could increase ARPU further.

    A lot of the existing installed base is using a product that was sold as a capital sale with a small service and maintenance contract, not SaaS. Since 1 November 2019, all quotes and proposals are SaaS contracts. These new deals comprise multiple products. In the second quarter of FY21, ARPU on new deals was between US$1.75 to US$4.30.

    Volpara has explained that identifying women who should get genetics testing can lead to a significantly increased ARPU.

    Increasing market share

    The business has significantly increased its market share over the last few years thanks to acquisitions like MRS Systems and CRA Health.

    Volpara’s market share increased in FY21 to 32% of US women having a group product applied on their images and data. That compares to approximately 27% at the end of FY20.

    The CRA Health acquisition came with a market share of approximately 6%, as well as the integration with electronic health records (EHR).

    Strong gross profit margin

    The Volpara gross profit margin continues to grow. It is one of the highest on the ASX. In FY20 the gross profit margin was 86% and in FY21 the margin increased another five percentage points to 91%. This could be an important driver for the Volpara share price over time. 

    That means a lot of the new revenue can fall to the next profit line in the accounts. Over the longer-term, the gross margin could rise even more and help the net profit improve at a relatively fast rate.

    The post 3 reasons why the Volpara (ASX:VHT) share price could be a buy appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/34HfErY

  • 2 quality ETFs that could give your portfolio a boost

    Exchange traded funds (ETFs) can be a fantastic way to balance out your portfolio. This is because ETFs provide investors with easy access to a large and diverse group of shares that you wouldn’t normally have access to.

    With that in mind, I have picked out two ETFs that are popular with investors right now. Here’s what you need to know about them:

    VanEck Vectors Video Gaming and eSports ETF (ASX: ESPO)

    The first ETF to consider is the VanEck Vectors Video Gaming and eSports ETF. This ETF gives investors exposure to a portfolio of the largest companies involved in video game development, eSports, and gaming related hardware and software globally.

    The fund manager points out that these companies are well-placed to benefit from the increasing popularity of video games and eSports.

    In addition to this, VanEck believes this ETF would be a good option for investors that already have exposure to FAANG stocks or want alternative options in the tech sector.

    Among the fund’s largest holdings are graphics processing units giant Nvidia and games developers Take-Two Interactive (GTA, Red Dead), Electronic Arts (FIFA, Sims, Apex Legends), and Activision Blizzard (Call of Duty).

    Vanguard MSCI Index International Shares ETF (ASX: VGS)

    If diversification is your aim, then you’ll find it hard to beat the Vanguard MSCI Index International Shares ETF.

    This ETF gives investors a slice of over 1,500 of the world’s largest listed companies from major developed countries.

    This means you’ll be buying global giants such as Amazon, Apple, Facebook, Home Depot, Johnson & Johnson, Nestle, Procter & Gamble, Tesla, and Visa.

    Vanguard believes that this ETF would be suitable for buy and hold investors that are seeking long-term capital growth, international diversification, and some income. In respect to the latter, the fund currently offers a 1.6% dividend yield.

    The post 2 quality ETFs that could give your portfolio a boost appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/3g5bQpH

  • Why Jeremy Grantham is wrong about a share market bubble

    Legendary investor Jeremy Grantham is warning anyone who’ll listen that share markets have formed a big bubble about to burst.

    The co-founder of GMO said it in January, then reiterated it again this week at an Australian investor conference.

    “The Nasdaq Composite (INDEXNASDAQ: .IXIC) peaked quite a long time ago,” he said this week.

    “Maybe in a few months the termites might get to the rest of the market.”

    According to Grantham at the start of the year, the market was characterised by “extreme overvaluation, explosive price increases, frenzied issuance, and hysterically speculative investor behavior”.

    “I believe this event will be recorded as one of the great bubbles of financial history – right along with the South Sea bubble, 1929, and 2000,” he said.

    “Make no mistake – for the majority of investors today, this could very well be the most important event of your investing lives.”

    Grantham is famous for predicting the dot-com bust and global financial crisis crash, so people listen when he speaks.

    But one investment executive reckons the perma-bear deserves to be completely ignored.

    If you’re always a bear, you’ll be right some of the time

    The trouble with bears, according to Bell Potter director Richard Coppleson, is that they will be smug from inevitably being right some of the time.

    If you keep saying every 6 months the market will crash, you are not actually predicting anything. You’ll merely be correct some of the time because the market naturally goes through ups and downs.

    “In an article I read about 8 months ago, several well-known fund managers were warning that dark times were coming and that this rally had gone too far,” he posted on Livewire.

    “But then I stopped and thought, ‘Hey wait a minute — I actually read the exact same stuff from most of these fund managers 11 months ago, 8 months ago, 5 months ago and again now.’”

    And this behaviour is exactly what Coppleson accuses Grantham of doing.

    “It’s worth realising he has been a bear for a very long time,” said Coppleson.

    “Given we see these falls every decade or so (1987, 2000, 2008/2009, 2020), it’s only a matter of time until he is ‘proven right’ (and then the media will proclaim that ‘he picked it’).”

    To demonstrate, he noted Grantham famously predicted doom for equities in 2010, 2011, 2012, 2013, 2014 and 2015.

    “So if one day we see another market crash of say -25% or more, then he would be proven 100% correct and be able to claim he called it.”

    Coppleson said that if an investor listened to Grantham and held back for the last 10 years, they would have missed a 265% return on the US market, not even including dividends.

    “Right now many are ‘nervous’ after his big call – but it’s the same call we have heard now for at least 10 years.”

    Pre-COVID forces will be back

    Two Australian experts thought that the current ‘inflation fear’ conditions would not last.

    Technology and automation is taking over human labour, and that will drive prices for consumers down in the long run.

    “It is important for investors to remember the long-term narrative,” said Montgomery Investments chief investment officer Roger Montgomery.

    “Inflation will bounce around in the short and even medium term but structurally it appears to be heading interminably down. Lower inflation appears to be a structural reality.”

    Forager Funds chief investment officer Steve Johnson agreed that, while the market’s already seen “a violent sell-off” of growth stocks, they will not be in permanent decline.

    In fact, it’s a nice time to buy.

    “We’ve got a good list of probably 8 to 10 businesses that we’d love to own at the right price that are a lot closer to it today,” he told a Forager video.

    “So if this goes on for a few more months, you can expect to see a few more new names in the Australian Fund portfolio.”

    The post Why Jeremy Grantham is wrong about a share market bubble appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/3fOfuW7

  • 2 ASX dividend shares that could help you beat low interest rates

    If you’re fed up with low interest rates, you’re not alone. But don’t worry, because the Australian share market is here to save the day with its countless dividend options.

    Two ASX dividend shares that can help you beat low interest rates are listed below:

    Charter Hall Social Infrastructure REIT (ASX: CQE)

    The first ASX dividend share to consider is the Charter Hall Social Infrastructure REIT. It is a high quality real estate investment trust with a focus on properties with specialist use, limited competition, and low substitution risk.

    Among its portfolio you will find bus depots, police and justice services facilities, and childcare centres. In respect to the latter, the Charter Hall Social Infrastructure REIT is actually the largest owner of early learning centres in Australia. At the last count, it actively partnered with 35 high quality childcare operators.

    The Charter Hall Social Infrastructure REIT has been in strong form this year, reporting a 14.1% increase in operating earnings to $29.1 million during the first half. This allowed management to upgrade its FY 2021 distribution guidance to 15.7 cents per unit.

    Based on the current Charter Hall Social Infrastructure share price, this represents a 4.6% yield.

    Westpac Banking Corp (ASX: WBC)

    Another dividend share to look at is Westpac. Australia’s oldest bank has had a tough few years, but looks well-placed for growth again. This is thanks to improving trading conditions, a booming housing market, cost cutting, and the relaxing of responsible lending rules.

    It was thanks to these factors that the banking giant smashed expectations during the first half of FY 2021. For the six months ended 31 March, Westpac reported cash earnings of $3,537 million. This was a 256% increase over the prior corresponding period and a 119% lift over the second half of FY 2020.

    Analysts at Citi are positive on Westpac and have recently retained their buy rating and $29.50 price target on the company’s shares. The broker is also forecasting fully franked dividends per share of $1.16 and $1.18 over the next two years.

    Based on the latest Westpac share price of $26.50, this will mean yields of 4.5% and 4.7%, respectively.

    The post 2 ASX dividend shares that could help you beat low interest rates appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/3pk37UX

  • 5 things to watch on the ASX 200 on Friday

    On Thursday the S&P/ASX 200 Index (ASX: XJO) was on form again and charged to a new record high. The benchmark index rose 0.6% to 7,260.1 points.

    Will the market be able to build on this on Friday? Here are five things to watch:

    ASX 200 expected to edge higher

    The Australian share market looks set to end the week on a subdued note. According to the latest SPI futures, the ASX 200 is expected to open the day 3 points higher this morning. This is despite it being a poor night of trade on Wall Street, which saw the Dow Jones fall 0.1%, the S&P 500 drop 0.35%, and the Nasdaq tumble 1% lower.

    Oil prices rise

    Energy producers including Santos Ltd (ASX: STO) and Woodside Petroleum Limited (ASX: WPL) will be on watch after oil prices edged higher. According to Bloomberg, the WTI crude oil price is up 0.1% to US$68.88 a barrel and the Brent crude oil price is up slightly to US$71.36 a barrel. A mixed US inventory report held back oil prices.

    Tech shares on watch

    Australian tech shares such as Afterpay Ltd (ASX: APT) and Appen Ltd (ASX: APX) could come under pressure today after their US counterparts were sold off overnight. The tech-heavy Nasdaq index fell 1% after investors rotated into cyclical stocks. As the local tech sector has a tendency to follow the Nasdaq’s lead, it doesn’t bode well for Friday’s trade.

    Wesfarmers given buy rating

    The Wesfarmers Ltd (ASX: WES) share price is in the buy zone according to analysts at Goldman Sachs. In response to its strategy update on Thursday, the broker has retained its buy rating and $59.70 price target. Goldman notes that key priorities have been aligned towards developing a market leading data and digital ecosystem, investing in platforms, and accelerating the pace of continuous improvement.

    Gold price sinks

    Gold miners Newcrest Mining Ltd (ASX: NCM) and St Barbara Ltd (ASX: SBM) could end the week in the red after the gold price sank. According to CNBC, the spot gold price is down 1.9% to US$1,873.20 an ounce. A strong US dollar put pressure on the safe haven asset.

    The post 5 things to watch on the ASX 200 on Friday appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/3pniZpt

  • Why the Australian Clinical Labs (ASX:ACL) share price soared 5% today

    The Australian Clinical Labs Ltd (ASX: ACL) share price climbed to a new high of $3.88 during trading today. This follows the pathology service provider’s announcement that it has upgraded its earnings forecast for the 2021 financial year.

    At close of trading, the company’s shares had lowered slightly to $3.74, but were still up 5.35%.

    What did Australian Clinical Labs announce?

    Investors drove up the Australian Clinical Labs share price after the company provided an improved performance outlook.

    In a statement to the ASX, the company stated it had exceeded its original projections in the prospectus released in late April.

    The revised FY21 guidance is forecasting total revenue of between $657.7 million and $663.3 million. This is up to 3% higher than the $647 million projected in the prospectus.

    Earnings before interest, tax, depreciation and amortisation (EBITDA) is also expected to surge by between $217.4 million and $222.3 million. The adjusted result reflects a lift of up to 7% on the $207.7 million assumed in April.

    And lastly, net profit after tax (NPAT) is predicted to jump by between $82 million and $85.4 million. In comparison to the $74.5 million stated in the prospectus, this is an increase of up to 15%.

    Australian Clinical Labs noted the boost in numbers was driven by revenue growth, with costs kept in line or below the prospectus forecasts. In addition, the prospectus contained just 7 months of actual result, with the 5 remaining months based on company projections.

    Australian Clinical Labs CEO and executive director Melinda McGrath commented:

    We are pleased with the positive momentum across the business despite the continued uncertainties arising from COVID-19. It is anticipated that the FY21 pro-forma NPAT will be 10% to 15% higher than the FY21 forecast disclosed in the prospectus.

    Share price snapshot

    Australian Clinical Labs is a leading provider of pathology services in Australia. The company has 86 laboratories accredited by the National Association of Testing Authorities and performs a comprehensive range of services for doctors, patients and corporate clients. 

    Since listing on the ASX in mid-May at a price of $4 apiece, Australian Clinical Labs shares are slightly down.

    Australian Clinical Labs has a market capitalisation of roughly $760 million, with more than 201 million shares outstanding.

    The post Why the Australian Clinical Labs (ASX:ACL) share price soared 5% today appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/3uLNy9q

  • 2 beaten down ASX tech shares that could be in the buy zone

    The tech sector has been underperforming in recent months. While this is disappointing, it has potentially created a buying opportunity for patient and long term focused investors.

    Two ASX tech shares that are trading notably lower than their 52-week highs are listed below. Here’s what you need to know about them:

    Adore Beauty Group Limited (ASX: ABY)

    The Adore Beauty share price is down 44% from its 52-week high. This could make it worth considering an investment in Australia’s leading online beauty retailer according to analysts at Morgan Stanley.

    Late last month, the broker retained its overweight rating and $5.00 price target on its shares.

    While Morgan Stanley suspects that Adore Beauty’s growth may slow materially in the near term as it cycles heightened sales during the pandemic, it remains positive on the long term. This is due to Adore Beauty being the leader in a structural growth market.

    The Adore Beauty share price is currently trading at $4.14.

    Appen Ltd (ASX: APX)

    Another beaten down ASX tech share to look at is Appen. The artificial intelligence (AI) data annotation products and solutions provider’s shares are down 70% from their 52-week high.

    This has been driven partly by concerns over demand for its services from some of its largest customers (due to COVID-19 headwinds) and its ability to achieve guidance in FY 2021.

    While the near term could be tough, its long term outlook appears positive due to its leadership position in a growing market. Appen also has a strong position in the government sector thanks to its acquisition of Figure Eight. This is a big positive as governments across the world are investing billions into AI.

    Late last month, analysts at Ord Minnett put a buy rating and $24.75 price target on the company’s shares. This compares to the latest Appen share price of $13.06.

    The post 2 beaten down ASX tech shares that could be in the buy zone appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/2TsDKEj